张玉晶 - 中山大学 - 肿瘤防治中心

个人简介

2002-至今中山大学肿瘤防治中心放疗科主治医师、副主任医师（2004）、主任医师（2010） 2010-2011 新疆医科大学肿瘤医院放疗科副主任、援疆专家 2008-2009 Baylor医学院/得克萨斯儿童癌症中心博士后研究助理 2007-2008 得克萨斯大学M.D.安德森癌症中心访问学者 1999-2002 中国协和医科大学/中国医学科学院肿瘤医院放射肿瘤学博士研究生 1995-1999 山东大学齐鲁医院肿瘤中心放疗科住院医师、主治医师 1992-1995 山东医科大学普外科专业硕士研究生 1986-1992 山东医科大学临床医学六年制英语医学班

研究领域

从事肿瘤放射治疗20余年，专长于淋巴瘤、胃癌、胆胰肿瘤、乳腺癌和软组织肉瘤的放射治疗和综合治疗。其中，对结外鼻型NK/T细胞淋巴瘤和其他结外原发淋巴瘤的调强放疗，对胃癌的术前、术后放化疗以及胆胰肿瘤的调强放射治疗积累了较丰富的经验；对乳腺癌的放射治疗技术和早期乳腺癌的放疗指征有细致的研究。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Feng LL, et al. CT-based Vessel-guided Lymphatic Delineation of 211 patients for Defining the Target Volume of Perigastric Lymph Nodes in Gastric Cancer. Oncology Letters. [Accepted for publication] 2.Wen G, et al. Management of extramedullary plasmacytoma: role of radiotherapy and prognostic factor analysis in 55 patients. Chinese Journal of Cancer Research [Accepted for publication] 3.孟凡军，郭建贵，林尤恩，张玉晶. 71例原发颅内中枢神经系统DLBCL预后分析. 中华放射肿瘤学杂志. 2017 Vol. 26 (8): 909-913. 4.Huang YH, Rao HL, Yan SM, Wang F, Wu QN, Feng YF, Zhang YJ*. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution. Ann Hematol. 2017 Aug; 96(8):1331-1342.（IF：3.022） 5.Xu S, Feng L, Chen Y, Sun Y, Lu Y, Huang S, Fu Y, Zheng R*, Zhang YJ*, Zhang R*. Consistency mapping of 16 lymph node stations in gastric cancer by CT-based vessel-guided delineation of 255 patients. Oncotarget. 2017 Jun 20; 8(25): 41465- 41473. （IF：5.168） 6.Niu SQ, Wen G, Ren YF, Li YY, Feng LL, Wang CT, Huang XB, Wen BX, Zhang YJ*. Predictive Value of Primary Tumor Site for Loco-regional Recurrence in Early Breast Cancer Patients with One to Three Positive Axillary Lymphadenophy. J Cancer. 2017; 8(12): 2394-2400.（IF：3.609）. 7.Wang QX, Li SH, Ji BY, Wang HY, Li YY, Feng LL, Chen K*, Xia YF, Zhang YJ*. Lymphocyte/Monocyte Ratio is a Novel Predictor for Early Stage Extranodal Natural Killer/T-cell Lymphoma, Nasal Type. J Cancer. 2017 Apr 8; 8(6): 1030-1037. （IF：3.609） 8.Li YY, Lin HQ, Zhang LL, Feng LL, Niu SQ, Wang HY, Zhang YJ*, Wang XC*. Intensity-modulated radiotherapy has superior outcomes to three-dimensional conformal radiotherapy in patients with stage IE-IIE extranodal nasal-type natural killer/T-cell lymphomatype nature killer/T-cell lymphoma. Oncotarget. 2017 Mar 11;8(36):60504-60513. （IF：5.168） 9.Wang JH, Bi XW, Li PF, Xia ZJ, Huang HQ, Jiang WQ, Zhang YJ, Wang L. Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type. J Cancer. 2017 Feb 25;8(5):793-800. （IF：3.609） 10.Li YY, Feng LL, Niu SQ, Wang HY, Zhang LL, Wang L, Xia ZJ, Huang HQ, Xia YF, Zhang YJ*, Wang XC*. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy. Oncotarget. 2017 Feb 14; 8(7): 11480-11488. （IF：5.168） 11.童琴，罗燕容，张玉晶*，冯玲玲，李贻阳，王汉瑜，夏云飞，艾小红. 局部区域复发的结外鼻型NK/T细胞淋巴瘤挽救治疗的疗效和预后分析. 中华放射肿瘤学杂志. 2017;26 (1):45-49. 12.Yang Y, Cao JZ, Lan SM, Wu JX, Wu T, Zhu SY, Qian LT, Hou XR, Zhang FQ, Zhang YJ, Zhu Y, Xu LM, Yuan ZY, Qi SN, Li YX. Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma. JAMA Oncol. 2017 Jan 1;3(1):83-91. 13.冯玲玲，张玉晶*，李绮雯，李贻阳，王俏镟，曾智帆，周志伟. 不能切除和复发的局部进展期胃癌放射治疗的疗效分析. 中华放射肿瘤学杂志. 2016; 25 (11): 1209-1213. 14.Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, Huang HQ, Jiang WQ, Zhang YJ, Wang L. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016 Oct 13; 9(1): 109. 15.Wang L, Bi XW, Xia ZJ, Huang HQ, Jiang WQ, Zhang YJ*. Radiation dose reduction for patients with extranodal NK/T-cell lymphoma with complete response after initial induction chemotherapy. Onco Targets Ther. 2016 Sep 26; 9: 5875-5881. 16.Wen G, Zhang JS, Zhang YJ*, Zhu YJ, Huang XB, Guan XX. Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy. J Breast Cancer. 2016 Jun; 19(2): 176-184. （IF：1.854）